HOME >> BIOLOGY >> NEWS
BresaGen announces Australia's first cloned pig

Australian biotechnology company, BresaGen Limited, in association with the Immunology Research Centre, St Vincent's Hospital Melbourne, has made a major breakthrough in cloning technology.

Australia's first cloned pig is now five weeks old, has been weaned and is healthy and growing normally.

It is anticipated that the new cloning technology will have a major impact in guarding against the outbreak of animal disease and in the area of xenotransplantation - the use of animal organs for transplantation into humans.

The most obvious commercial use for cloning technology is the improved breeding of livestock. Cloning allows breeders to take a small number of animals with superior genetics and rapidly produce more.

BresaGen Program Leader Dr Mark Nottle described it as "a very good result considering that this was the first transfer using our new method."

"In addition to gains in productivity, cloning could be very useful in guarding against an outbreak of diseases such as Foot and Mouth," Dr Nottle said. "Once an animal is identified as having natural resistance to a particular disease, a breeding company would use cloning to produce large numbers of animals. These animals would be supplied to farmers as breeding stock for new herds."

BresaGen President & CEO, Dr John Smeaton, said the technology used to clone the pig was unique.

"It is significantly different from the technology used to make Dolly the sheep," he explained. "Basically what works in sheep doesn't work in pigs, so we had to start from scratch. Consequently we have something new for the pig and have filed a patent application. This is an excellent result for BresaGen and is indicative of the technical strength the company has in the field of reproductive biology and embryo research."

A further application, and one of particular interest to the medical community, is xenotransplantation. Every year thousands of people around the world die while waiting for organ transplanta
'"/>

Contact: Dr Meera Verma
JAnderson@bresagen.com.au
618-8150-8220
Adelaide University
8-May-2001


Page: 1 2

Related biology news :

1. Secretary of Energy announces seven E.O. Lawrence Award Winners
2. Popular Science announces Third Annual Brilliant 10
3. The American Phytopathological Society announces 2004 awards
4. NSF announces six FIBR awards to tackle some of biologys most challenging questions
5. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
6. JGI announces community sequencing program portfolio
7. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
8. National Corn Growers Association announces valuable maize genome data now available to scientists
9. DFG announces three percent budget increase
10. Chemical Society announces EPA awards for environmentally friendly technology
11. Nanosphere announces genetic detection advance in Nature Biotechnology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: BresaGen announces Australia first cloned pig

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: